Protalix BioTherapeutics (PLX) Short-term Investments (2020 - 2026)

Protalix BioTherapeutics' Short-term Investments history runs 7 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 34.04% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 34.04% decrease from a year earlier, with the FY2025 full-year figure at $15.6 million, up 3.47% from the prior year.
• Short-term Investments slipped to $10.1 million in Q1 2026 per PLX's latest filing, from $15.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $21.6 million in Q2 2024 and bottomed at $5.1 million in Q4 2022.
• The 5-year median for Short-term Investments is $15.7 million (2025), against an average of $15.6 million.
• Across the five-year window, Short-term Investments plunged 73.46% in 2022 and surged 312.82% in 2023, its largest moves.
• Year by year, Short-term Investments stood at $5.1 million in 2022, then soared by 312.82% to $20.9 million in 2023, then decreased by 27.98% to $15.1 million in 2024, then gained by 3.47% to $15.6 million in 2025, then tumbled by 35.34% to $10.1 million in 2026.
• Per Business Quant, the three latest PLX Short-term Investments figures stand at $10.1 million (Q1 2026), $15.6 million (Q4 2025), and $15.7 million (Q3 2025).